BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8547469)

  • 21. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
    Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of hypothalamus and ovary on pituitary function in transgenic mice expressing the bovine growth hormone gene and in growth hormone-deficient Ames dwarf mice.
    Chandrashekar V; Bartke A
    Biol Reprod; 1996 May; 54(5):1002-8. PubMed ID: 8722619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone, estradiol, and inhibin regulation of follicle-stimulating hormone and luteinizing hormone surges: implications for follicle emergence and selection in heifers.
    Haughian JM; Ginther OJ; Diaz FJ; Wiltbank MC
    Biol Reprod; 2013 Jun; 88(6):165. PubMed ID: 23658431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute follicular response to FSH in heifers downregulated long term with a GnRH agonist and with suppressed ovarian follicular growth.
    D'Occhio MJ; Cremonesi F; Trigg TE; Aspden WJ; Baruselli PS
    Theriogenology; 2013 Dec; 80(9):999-1005. PubMed ID: 23998741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression in the secretion of follicle-stimulating hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonadotropin-releasing hormone agonist.
    Gong JG; Campbell BK; Bramley TA; Gutierrez CG; Peters AR; Webb R
    Biol Reprod; 1996 Jul; 55(1):68-74. PubMed ID: 8793060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
    Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
    J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children.
    Wide L; Albertsson-Wikland K; Phillips DJ
    J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
    Kumar TR; Palapattu G; Wang P; Woodruff TK; Boime I; Byrne MC; Matzuk MM
    Mol Endocrinol; 1999 Jun; 13(6):851-65. PubMed ID: 10379885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice.
    Yang WL; Cai KQ; Smedberg JL; Smith ER; Klein-Szanto A; Hamilton TC; Xu XX
    Am J Pathol; 2007 Apr; 170(4):1325-36. PubMed ID: 17392171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
    Bhasin S; Berman N; Swerdloff RS
    J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uterotropic hormones produced by ovaries of Sl/Slt mutant mice before spontaneous development of tubular adenomas.
    Terada N; Kuroda H; Matsumoto K; Kitamura Y
    Jpn J Cancer Res; 1985 Jul; 76(7):590-5. PubMed ID: 3928555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
    Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
    J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induced ovulation and changes in pituitary responsiveness to continuous infusion of gonadotropin-releasing hormone during the ovarian cycle in the bullfrog, Rana catesbeiana.
    McCreery BR; Licht P
    Biol Reprod; 1983 Nov; 29(4):863-71. PubMed ID: 6416318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice.
    Cai KQ; Wang Y; Smith ER; Smedberg JL; Yang DH; Yang WL; Xu XX
    Neoplasia; 2015 Jan; 17(1):89-100. PubMed ID: 25622902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of deslorelin acetate implants in horses: single implants in stallions and steroid-treated geldings and multiple implants in mares.
    Johnson CA; Thompson DL; Cartmill JA
    J Anim Sci; 2003 May; 81(5):1300-7. PubMed ID: 12772858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.